<DOC>
	<DOC>NCT02584855</DOC>
	<brief_summary>The main purpose of this study is to evaluate the safety and long-term efficacy of ixekizumab compared to placebo in participants with active psoriatic arthritis.</brief_summary>
	<brief_title>A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Presents with established diagnosis of active psoriatic arthritis (PsA) for at least 6 months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria Active PsA defined as the presence of at least 3 tender and at least 3 swollen joints Presence of active psoriatic skin lesion or a history of plaque psoriasis (Ps) Men must agree to use a reliable method of birth control or remain abstinent during the study Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment Have been treated with 1 or more conventional diseasemodifying antirheumatic drugs (cDMARDs) Current or prior use of biologic agents for treatment of Ps or PsA Inadequate response to greater than or equal to 4 conventional diseasemodifying antirheumatic drugs (DMARDS) Current use of more than one cDMARDs Diagnosis of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA Have received treatment with interleukin (IL) 17 or IL12/23 targeted monoclonal antibody (MAb) therapy Serious disorder or illness other than psoriatic arthritis Serious infection within the last 3 months Breastfeeding or nursing (lactating) women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Spondyloarthritis</keyword>
	<keyword>Spondylarthropathy</keyword>
</DOC>